

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Stem Cells

ESPS manuscript NO: 16168

Title: High dose chemotherapy with stem cell support in the treatment of testicular cancer

Reviewer's code: 02446114

Reviewer's country: Taiwan

Science editor: Xue-Mei Gong

Date sent for review: 2015-01-01 20:06

Date reviewed: 2015-01-16 10:00

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

It is a good paper for reader of WJSC.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Stem Cells

ESPS manuscript NO: 16168

Title: High dose chemotherapy with stem cell support in the treatment of testicular cancer

Reviewer's code: 02446080

Reviewer's country: Venezuela

Science editor: Xue-Mei Gong

Date sent for review: 2015-01-01 20:06

Date reviewed: 2015-01-20 00:57

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The article "The role of high dose chemotherapy and stem cell transplantation in the treatment of metastatic testicular cancer" is a comprehensive, up-to-date and relevant review about very relevant current treatment options for life-threatening testicular cancer types. The article provides very complete information while at the same time keeping brevity and objectivity. Consider giving information on the title about the specific stem cell type issued in the article: "The role of high dose chemotherapy and haematopoietic stem cell transplantation in the treatment of metastatic testicular cancer" See below some issues that should be addressed by the authors (other minor corrections are done directly in the manuscript with the track-changes function): Some citation numbers are located in the middle of sentences and should be at the end. For instance: in "After that, Schmoll et al. from German Testicular Cancer Study Group (GTCSG) published a phase I/IIa study (18) where they treated poor prognosis TGCC patients with VIP-escalated protocol." Place the reference at the end: "After that, Schmoll et al. from German Testicular Cancer Study Group (GTCSG) published a phase I/IIa study where they treated poor prognosis TGCC patients with VIP-escalated protocol (18)."

Another example: "After the positive outcome in poor-mobilisers with lymphoma and multiple myeloma (54) increased enthusiasm for using plerixafor to mobilize hematopoietic stem cells in patients with TGCC." Check this through the text. The following sentences are difficult to understand. Please rephrase: "Even there is no poistive randomized study to prove HDCT concept cure rates in relapsed TGCC are higher after high dose therapy then in standard chemotherapy." "The rationale of a high dose chemotherapy in chemo-sensitive cancer changed directed researches to high dose chemotherapy with autologous stem cell transplantation (3, 14)." "Benefit of a high dose chemotherapy had only those patients with the unsatisfactory decline of tumor markers." "Two-year PFS and five years OS was longer in the group with HDCT 27.8% vs. 49.6% (HR 0.44; $p < 0.001$), 40.8% vs 53.2% (HR 0.65; $p < 0.001$)" (What is confusing here is the presentation of the data, please rearrange and/or give better sense to it) "After the positive outcome in poor-mobilisers with lymphoma and multiple myeloma (54) increased enthusiasm for using plerixafor to mobilize hematopoietic stem cells in patients with TGCC." "The remaining three, poor-mobilisers, they have amassed an adequate number after applying plerixafor" Table 1 legend: Where is this data from? (what is the context, own data, etc?) There is a considerably high number of abbreviations in the manuscript. Please express in full length the first time it is mentioned in the text (also in figure legends in which these expressions should also appear in-full, independently of whether they have been used or not in the text), particularly: ASCT GTC SG CEC CDCl GCC EGNSGCT IA NSGCT ASCO Figure 1 legend: Please express abbreviations in full, extended form (independently of already done in the main body text of the manuscript).

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Stem Cells

ESPS manuscript NO: 16168

Title: High dose chemotherapy with stem cell support in the treatment of testicular cancer

Reviewer's code: 00740391

Reviewer's country: India

Science editor: Xue-Mei Gong

Date sent for review: 2015-01-01 20:06

Date reviewed: 2015-01-05 16:22

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Good article - needs minor language revision.